Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates

Zhang, Ningyan; Williams, Brent R.; Lü, Ping; An, Zhiqiang; Chin, Chen Ni

doi:10.1002/9780470485408.ch31

Cited by 3 publications

(1 citation statement)

References 287 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proteins displayed on the surfaces of tumor cells are attractive molecules for the inhibition of key signaling pathways by “naked” stand-alone monoclonal antibodies [ 28 ] or for selective delivery of cytotoxic molecules via monoclonal antibody-drug conjugates [ 18 , 29 ]. Mechanisms of therapeutic action for these biological drugs may include producing programmed cell death, blocking growth factor receptors, arresting proliferation of tumor cells, inducing antibody-mediated cell killing via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or the delivery of cytotoxic payloads that act to truncate DNA synthesis or inhibit microtubules [ 30 ]. Immunotherapy using monoclonal antibodies holds considerable promise as an anti-cancer therapeutic strategy because of its ability to target cancer cells specifically while sparing surrounding normal untransformed tissue [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors

et al. 2015

View full text Add to dashboard Cite

The metalloproteinase SAS1B [ovastacin, ASTL, astacin-like] was immunolocalized on the oolemma of ovulated human oocytes and in normal ovaries within the pool of growing oocytes where SAS1B protein was restricted to follicular stages spanning the primary-secondary follicle transition through ovulation. Gene-specific PCR and immunohistochemical studies revealed ASTL messages and SAS1B protein in both endometrioid [74%] and malignant mixed Mullerian tumors (MMMT) [87%] of the uterus. A MMMT-derived cell line, SNU539, expressed cell surface SAS1B that, after binding polyclonal antibodies, internalized into EEA1/LAMP1-positive early and late endosomes. Treatment of SNU539 cells with anti-SAS1B polyclonal antibodies caused growth arrest in the presence of active complement. A saporin-immunotoxin directed to SAS1B induced growth arrest and cell death. The oocyte restricted expression pattern of SAS1B among adult organs, cell-surface accessibility, internalization into the endocytic pathway, and tumor cell growth arrest induced by antibody-toxin conjugates suggest therapeutic approaches that would selectively target tumors while limiting adverse drug effects in healthy cells. The SAS1B metalloproteinase is proposed as a prototype cancer-oocyte tumor surface neoantigen for development of targeted immunotherapeutics with limited on-target/off tumor effects predicted to be restricted to the population of growing oocytes.

show abstract

Section: Discussionmentioning

confidence: 99%

Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors

et al. 2015

View full text Add to dashboard Cite

show abstract

Therapeutic Monoclonal Antibodies

2009

View full text Add to dashboard Cite

Nanomedicine: is It Lost in translation?

et al. 2018

View full text Add to dashboard Cite

By the end of 2017 more than 200,000 scientific research articles had been published about nanomedicine. Out of this vast number only a few of the reported nanoconstructs reached clinical trials for various applications, including the diagnosis and treatment of several cancers, and the treatment of infections and other non-cancerous diseases. 30 years after the pioneering work in this field of research, the low product yield at the end of research pipeline leads to a question that is asked by many: 'had nanomedicine been lost in translation?' In this review, we will discuss the landscape of nanomedicine regarding cancer treatment and miscellaneous applications as well as some obstacles toward full utilization of this powerful therapeutic tool and suggest a few solutions to improve the current translational value of nanomedicine research.

show abstract

Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates

Cited by 3 publications

References 287 publications

Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors

Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors

Therapeutic Monoclonal Antibodies

Nanomedicine: is It Lost in translation?

Contact Info

Product

Resources

About